There are 3397 resources available
LBA26 - Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Final results of a phase III trial
Presenter: Pei-Rong Ding
Session: Proffered Paper session 1 - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast
Mechanisms of resistance
Presenter: Anne-Marie Baird
Session: Managing disease progression in oncogene-driven lung cancer
Resources:
Slides
Webcast
Luminal-like breast cancer
Presenter: Suzette Delaloge
Session: Optimal treatment sequence in metastatic breast cancer (mBC) in 2023
Resources:
Slides
Webcast
In metastatic and recurrence
Presenter: Nicoletta Colombo
Session: Integrating immunotherapy into the standard of care for cervical cancer
Resources:
Slides
Webcast
Novel neoadjuvant combination immunotherapies
Presenter: Alexander Menzies
Session: Is neoadjuvant immunotherapy a therapeutic platform for all tumour types?
Resources:
Slides
Webcast
Toxicity of IO + targeted agents
Presenter: Enrique Grande Pulido
Session: Management of novel treatments’ toxicities
Resources:
Slides
Webcast
1688O - Informative censoring of surrogate end-point data in FDA-approved cancer drugs
Presenter: Tomer Meirson
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1989MO - Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study
Presenter: Antonio Calles Blanco
Session: Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1689O - Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: A collaborative work from ESMO real-world data and Digital Health Working Group
Presenter: Anna Pellat
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
2033MO - The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor (ICI) therapy on overall survival (OS): A population-based study
Presenter: Lawson Eng
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast